Navigating a complex drug development landscape, sponsors must rethink their approach to risk in study design and execution.
Mary Gunn, PhD, MBA
Advertisement
CEO of Emerald Clinical Trials
Articles by Mary Gunn, PhD, MBA
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
FDA Releases Transparency Roadmap Outlining Disclosure Priorities Across Drug Development and Regulatory Review
2
FDA Seeks Public Input on Early-Phase Clinical Trial Design for Ibogaine
3
Beyond the Molecule: Why Radiopharmaceutical Trials Require a New Operating Model
4
Mixed Outsourcing Models Are Spreading. Is Sponsor Oversight Keeping Up?
5